Melissa Pilewskie1, Michelle Stempel2, Hope Rosenfeld2, Anne Eaton3, Kimberly J Van Zee2, Monica Morrow2. 1. Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. pilewskm@mskcc.org. 2. Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abstract
BACKGROUND: The Surgery Versus Active Monitoring for Low-Risk DCIS (LORIS) trial is studying the safety of monitoring core-biopsy diagnosed low-risk ductal carcinoma in situ (DCIS) without excision. We sought to determine the incidence and characteristics of synchronous invasive carcinoma found in LORIS-eligible women who underwent excision, as this knowledge is essential in assessing the safety of observation alone. METHODS: Women meeting LORIS eligibility criteria (age ≥46 years, screen-detected calcifications, non-high-grade DCIS diagnosed by core biopsy, absence of nipple discharge, or strong family history of breast cancer) who underwent surgical excision from 2009 to 2012 were identified. Histologic findings of excision specimens were reviewed. RESULTS: Overall, 296 LORIS-eligible cases were identified; 58 (20 %) had invasive carcinoma on final pathology (90 % invasive ductal, 78 % >1 mm in size, 21 % high grade, 3 % triple negative, 9 % HER2 amplified). Of these, 18 (31 %) were pT1b or larger and 3 (5 %) were pN1. Among eligible upgraded cases, 90 % received radiation, 89 % received endocrine therapy, and 18 % were recommended chemotherapy. Women upgraded to invasive carcinoma were more likely to have intermediate-grade DCIS on core biopsy and to have undergone mastectomy. CONCLUSIONS: Among LORIS-eligible women, 20 % had invasive carcinoma at surgical excision that was heterogeneous in grade, size, and receptor status. Information gained from surgical excision influenced receipt of adjuvant radiation and endocrine therapy in most patients, and indicated benefit from chemotherapy in 18 % of patients. Surgical excision is warranted until additional risk stratification is available to identify a cohort of DCIS patients at lower risk for clinically significant synchronous invasive carcinoma.
BACKGROUND: The Surgery Versus Active Monitoring for Low-Risk DCIS (LORIS) trial is studying the safety of monitoring core-biopsy diagnosed low-risk ductal carcinoma in situ (DCIS) without excision. We sought to determine the incidence and characteristics of synchronous invasive carcinoma found in LORIS-eligible women who underwent excision, as this knowledge is essential in assessing the safety of observation alone. METHODS:Women meeting LORIS eligibility criteria (age ≥46 years, screen-detected calcifications, non-high-grade DCIS diagnosed by core biopsy, absence of nipple discharge, or strong family history of breast cancer) who underwent surgical excision from 2009 to 2012 were identified. Histologic findings of excision specimens were reviewed. RESULTS: Overall, 296 LORIS-eligible cases were identified; 58 (20 %) had invasive carcinoma on final pathology (90 % invasive ductal, 78 % >1 mm in size, 21 % high grade, 3 % triple negative, 9 % HER2 amplified). Of these, 18 (31 %) were pT1b or larger and 3 (5 %) were pN1. Among eligible upgraded cases, 90 % received radiation, 89 % received endocrine therapy, and 18 % were recommended chemotherapy. Women upgraded to invasive carcinoma were more likely to have intermediate-grade DCIS on core biopsy and to have undergone mastectomy. CONCLUSIONS: Among LORIS-eligible women, 20 % had invasive carcinoma at surgical excision that was heterogeneous in grade, size, and receptor status. Information gained from surgical excision influenced receipt of adjuvant radiation and endocrine therapy in most patients, and indicated benefit from chemotherapy in 18 % of patients. Surgical excision is warranted until additional risk stratification is available to identify a cohort of DCIS patients at lower risk for clinically significant synchronous invasive carcinoma.
Authors: Harold J Burstein; Kornelia Polyak; Julia S Wong; Susan C Lester; Carolyn M Kaelin Journal: N Engl J Med Date: 2004-04-01 Impact factor: 91.245
Authors: Meagan E Brennan; Robin M Turner; Stefano Ciatto; M Luke Marinovich; James R French; Petra Macaskill; Nehmat Houssami Journal: Radiology Date: 2011-04-14 Impact factor: 11.105
Authors: Adele Francis; Jeremy Thomas; Lesley Fallowfield; Matthew Wallis; John M S Bartlett; Cassandra Brookes; Tracy Roberts; Sarah Pirrie; Claire Gaunt; Jennie Young; Lucinda Billingham; David Dodwell; Andrew Hanby; Sarah E Pinder; Andrew Evans; Malcolm Reed; Valerie Jenkins; Lucy Matthews; Maggie Wilcox; Patricia Fairbrother; Sarah Bowden; Daniel Rea Journal: Eur J Cancer Date: 2015-08-18 Impact factor: 9.162
Authors: Lotte E Elshof; Konstantinos Tryfonidis; Leen Slaets; A Elise van Leeuwen-Stok; Victoria P Skinner; Nicolas Dif; Ruud M Pijnappel; Nina Bijker; Emiel J Th Rutgers; Jelle Wesseling Journal: Eur J Cancer Date: 2015-05-26 Impact factor: 9.162
Authors: Mary F Dillon; Enda W McDermott; Cecily M Quinn; Ann O'Doherty; Niall O'Higgins; Arnold D K Hill Journal: J Surg Oncol Date: 2006-06-01 Impact factor: 3.454
Authors: Julie Bruce; Alison J Thornton; Rachael Powell; Marie Johnston; Mary Wells; Steven D Heys; Alastair M Thompson; Cairns W Smith; Alastair W Chambers; Neil W Scott Journal: Pain Date: 2013-10-04 Impact factor: 6.961
Authors: Lars J Grimm; Marc D Ryser; Ann H Partridge; Alastair M Thompson; Jeremy S Thomas; Jelle Wesseling; E Shelley Hwang Journal: Ann Surg Oncol Date: 2017-08-09 Impact factor: 5.344